Sector News

Clariant to acquire Hong Kong-based healthcare packaging firm VitaPac

September 29, 2014
Chemical Value Chain
Clariant’s existing portfolio of packaging solutions. Clariant says that it has signed a purchase agreement to acquire healthcare packaging company VitaPac (Hong Kong). Financial details of the deal were not disclosed. VitaPac, which was founded in 1995, generated sales of about 4 million Swiss francs ($4.2 million) in 2013. VitaPac employs about 80 people and has a production site at Dongguan, China. VitaPac develops and manufactures a full range of protective packaging solutions for the pharmaceutical, neutraceutical and food industries, as well as for the logistics and electronics sectors, mainly in the Asia/Pacific region. The company focuses on active sorbents and has established a leading market position for desiccant packets for moisture adsorption, Clariant says. The transaction is subject to regulatory approvals and is expected to be completed in the fourth quarter of 2014.
 
The bolt-on acquisition of VitaPac complements the portfolio of Clariant’s medical specialties business line within its masterbatches business unit. The deal will help Clariant to gain market share in important emerging markets especially in Asia but also to capture further sales in other regions. The acquired Dongguan plant will enlarge Clariant’s global footprint, furthering the reach to its multinational pharmaceutical customer base, the company says.
 
“The acquisition of VitaPac is in line with our strategy to grow profitably by investing in new technologies and new markets,” says Hariolf Kottmann, CEO of Clariant. “It will enable us to enhance Clariant’s existing portfolio of packaging solutions with new innovative products from the active packaging area, helping us to further develop our positioning in the medical specialties market,” Kottmann says.
 
VitaPac is known for its innovative, technology-driven product lines that address pharmaceutical stability and shelf life, Clariant says. The company maintains a drug master file (DMF) with the US FDA, and its products comply with all pertinent regulations for use in direct contact with food and drugs, Clariant says.
 
By Deepti Ramesh
 

comments closed

Related News

May 21, 2022

Sika opens new manufacturing plant in Bolivia 

Chemical Value Chain

Sika AG (Baar, Switzerland) has opened a new plant in Santa Cruz de la Sierra, thus doubling its production capacity for mortar and concrete admixtures in Bolivia. With this new facility in one of the country’s main industrial agglomerations, Sika is positioning itself for continued growth in the dynamic Bolivian construction market.

May 21, 2022

Chevron increases renewable fuel market share with REG acquisition

Chemical Value Chain

Chevron Corporation (NYSE: CVX) and Renewable Energy Group, Inc. (NASDAQ: REGI) (REG) announced on Monday a definitive agreement under which Chevron will acquire the outstanding shares of REG in an all-cash transaction valued at $3.15 billion, or $61.50 per share.

May 21, 2022

Lotte Chemical to invest $8 bn on hydrogen energy, battery materials by 2030

Chemical Value Chain

Lotte Chemical Corp. will invest 10 trillion won ($8 billion) on hydrogen and battery materials through 2030 to achieve annual revenue of 50 trillion won and carbon neutrality. The Korean chemical producer on Thursday unveiled its new corporate vision outlining key corporate strategies with focus on growth through hydrogen energy and battery materials businesses.